Factors influencing warfarin overdose in warfarin clinic of Satuek Hospital, Buriram Province

Main Article Content

Nakharin Somaboot

Abstract

This paper is aimed to study the factors that affect Warfarin overdose and its consequences. Samples were patients registered in the Warfarin clinic, Satuek Hospital who had INR more than 3.0 if they did not have Valve Replacement Surgery and INR more than 3.5 if they had Valve Replacement Surgery. There were 134 patients having abnormal INR in 2013. Questionnaire was used and descriptive statistics were expressed as frequency, percentage, mean, median and standard deviation. X2-test, Student T Test and Multiple Linear Regression were used to find the independent variables enhancing INR. Among them, 42.4 % were females. Majority of INR falling in the range from 3.0 to 4.0 was found in 63.7 %. The average Warfarin dosage was 23.1+4.1 mg/week. The most common indication was Atrial fibrillation found in 95.8 %. Around 35 % of patients took medicine improperly and the common unwanted symptoms such as bruises were found in 18.8 %. The low BMI (BMI < 20 kg/m2) and the Warfarin dosage of >20 mg/week were the two common causes of the INR ranging between 3.0-4.0 but no statistical significance (P=0.92 and 0.46, respectively) whereas the age over 60 years was the most common cause of INR ranging between >4.0-5.0 but no statistical significance (P=0.66). Focus on diseases relating to increased INR, heart failure had higher risk of INR > 3 with statistical significance (odd ratio =1.108, P <0.001). Moreover, it was found that the more chronic diseases, the stronger relation with increased INR (r =0.351, P= 0.002). In conclusion, the risk factors contributing Warfarin overdose are age > 60 years, BMI < 20 kg/m2, hypertension, heart failure, GFR below 60 ml/min, Warfarin > 20 mg/week and patients with many chronic diseases so they should be treated carefully in order to prevent Warfarin overdose.

Article Details

How to Cite
Somaboot, N. . (2024). Factors influencing warfarin overdose in warfarin clinic of Satuek Hospital, Buriram Province . Maharat Nakhon Ratchasima Hospital Journal, 40(3), 163–170. Retrieved from https://he04.tci-thaijo.org/index.php/MNRHJ/article/view/1507
Section
Original Article

References

Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952-6.

Millican EA, Lenzini PA, Milliqan PE, et al. Geneticbased dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110: 1511-5.

Cooper GM, Johnson JA, Langaee TY, et al. A genomewide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-7.

Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.

Krittathanmakul S, Silapachote P, Pongwecharak J, et al. Effects of pharmacist counseling on outpatients receiving warfarin at Songklanagarind Hospital. Songklanagarind Med J 2006; 24: 93-9.

Li T, Lange LA, Li X, et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2008; 43: 740-4.

Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation

and warfarin dose. N Engl J Med 2005; 352: 2285- 93.

Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007; 5: 8-16.

Van den Besselaar AM, van der Meer FJ, Gerrits- Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol 1988; 90: 685-90.

Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and Cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-8.

Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80: 13-22.

Gong IY, Tirong RG, Schwartz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118: 3163-71.

Platt AB, Localio AR, Brensinger CM, et al. Risk factors for nonadherence to warfarin: results from the INRANGE study. Pharmacoepidemiol Drug Saf 2008; 17: 853-60.

Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. CHEST 2006; 130: 1390-6.

McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433m variant. Mol Pharmacol 2009; 75: 1337-46.